Whether the association between aldosterone activation and plasma FGF23 exists beyond kidney stone formers remains to be validated, e.g., in populations of healthy volunteers and of patients with chronic kidney disease or congestive heart failure. This evidence concerns the gene FGF23 and nephrolithiasis.